BioFactura’s Ustekinumab Biosimilar To Be Trialed As ‘Robotic’ Pill
US-Based Firm Signs Agreement With CA-Based Rani Therapeutics
BioFactura, which is already using its ‘StableFast’ technology platform to develop its biosimilar ustekinumab candidate, has allied with fellow US-based biotech Rani Therapeutics to see if the biologic can be formulated into Rani’s proprietary ‘robotic’ pill.
